Ascend Capital’s AnaptysBio ANAB Stock Holding History

Ascend Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-44,375	Closed	-$1.55M	–	213
2017 Q3	$1.55M	Buy	+44,375	New	+$1.2M	0.06%	144

Other funds holding ANAB

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ascend Capital's ANAB Position: Q4 2017 in Review

Ascend Capital sold out of AnaptysBio (ANAB) in Q4 2017, closing a stake of 44,375 shares — an estimated $1.55M sold.

Ascend Capital first reported a position in ANAB in Q3 2017 and held it in 1 quarter. The position peaked at $1.55M in Q3 2017. 116 funds tracked by Wall St. Rank hold ANAB as of Q4 2017.

Ascend Capital reported no remaining AnaptysBio position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 44,375 AnaptysBio shares in Q4 2017, an estimated $1.55M.
Ascend Capital first reported a position in AnaptysBio in Q3 2017 and held it in 1 quarter.
Ascend Capital's AnaptysBio position peaked at $1.55M in Q3 2017.
116 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.